Clinical Trial: A Phase II Trial of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07006077) titled 'A Phase II Trial of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer' on May 09.

Brief Summary: The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.

Study Start Date: June 03

Study Type: INTERVENTIONAL

Condition: Advanced Pancreatic Cancer

Intervention: BIOLOGICAL: Recombinant human IL-21-expressing oncolytic vaccinia virus injection

hV01 is a recombinant vaccinia ...